STAT Stitch Deep Dive Podcast Beyond The Bedside

STAT Stitch Deep Dive Podcast Beyond The Bedside

por Regular Guy

Cursos Ciencias de la Vida

Temporada 6

MH PHARM | Aripiprazole

Aripiprazole Overview & Mechanism of Action Aripiprazole is an atypical antipsychotic acting as a partial agonist at dopaminergic D2 and serotonergic 5-HT1A receptors, and an antagonist at 5-HT2A receptors. This unique mechanism stabilizes dopamine, limiting extrapyramidal side effects compared to older agents. It is FDA-approved for schizophrenia, bipolar I disorder, major depressive disorder (MDD) adjunct therapy, Tourette's syndrome, and autism-associated irritability. Critical Boxed Warnings Suicidality: There is an increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults (up to 24 years of age) when aripiprazole is used as an antidepressant. Dementia-Related Psychosis: Antipsychotics are not approved for treating dementia-related psychosis in the elderly due to significantly elevated mortality (often from heart failure or pneumonia) and cerebrovascular events like stroke. Formulations & Administration Protocols Oral Options: Available as immediate-release tablets, disintegrating tablets, oral solutions, and Mycite. Mycite contains an ingestible sensor tracked via a smartphone app, though it is not recommended for "real-time" emergency tracking. All oral forms may be administered without regard to meals. Short-Acting IM Injection: Utilized exclusively for acute agitation in schizophrenia or bipolar mania. Inject deeply into the muscle; intravenous and subcutaneous routes are strictly contraindicated. Extended-Release (LAI) IM Injections: Formulations like Abilify Maintena (monthly), Abilify Asimtufii (every 2 months), and Aristada provide maintenance therapy via deep gluteal or deltoid injection. LAIs are not approved for patients under 18 years of age. Crucial Rule: Tolerability with oral aripiprazole must be established (which takes up to 2 weeks) prior to initiating long-acting injections in aripiprazole-naive patients. Initiation requires 14 to 21 days of oral overlap or the use of Aristada Initio. Key Dosing Principles Schizophrenia & Bipolar I: Initiate at 10 to 15 mg/day PO for adults. The target maximum effective dose is 30 mg/day. MDD Adjunct: Start at 2 to 5 mg/day PO, adjusting up to 15 mg/day based on response. Pediatrics: Doses vary by weight and indication, with maximum PO doses of 30 mg/day for bipolar disorder, 15 mg/day for autism, and 20 mg/day for Tourette's. Adjustments: Aripiprazole undergoes extensive hepatic metabolism via CYP3A4 and CYP2D6. Dosages must be reduced by 50% to 75% in CYP2D6 poor metabolizers or when co-administered with strong CYP3A4 or CYP2D6 inhibitors. No hepatic or renal dose adjustments are required. Pharmacokinetics & Safety Profile Oral aripiprazole has an 87% bioavailability, achieving steady-state within 14 days with an elimination half-life of 75 hours. LAI half-lives range widely from 30 to 57 days. Common mild-to-moderate adverse reactions include headache (0-27%), weight gain (2.2-26.3%), drowsiness (3-23%), agitation (19%), and nausea (8-15%). Severe risks include tardive dyskinesia, neuroleptic malignant syndrome, seizures, and metabolic changes.

MH PHARM | Ziprasidone [Geodon]

1. Medication Name/Class Generic/Brand: Ziprasidone (Geodon). Class: Atypical Antipsychotic, Serotonin-Dopamine Antagonist (SDA). 2. Mechanism of Action Antagonizes dopamine D2 and serotonin 5-HT2A receptors. Modulating mesolimbic dopamine reduces positive symptoms; mesocortical serotonin modulation targets negative symptoms. 3. Expected Action/Therapeutic Effect Reduces positive and negative psychotic symptoms and rapidly controls acute agitation. 4. Indications Schizophrenia, Bipolar I (acute/maintenance), and acute agitation (IM route only). 5. Pharmacokinetics Absorption: PO bioavailability is ~60% but requires food to double absorption. Peak/Half-life: PO peaks in 6-8 hrs (half-life 7 hrs). IM peaks in ≤1 hr (half-life 2-5 hrs). Metabolism: Hepatic (minor CYP1A2/3A4 substrate). 6. Drug-Drug Interactions Has minimal CYP450 interference. Poses a high risk when combined with other CNS depressants or any QT-prolonging agents. 7. Side Effects vs Adverse Effects Common: Drowsiness, insomnia, weight gain, nausea, and EPS (akathisia). Serious: QT prolongation, Neuroleptic Malignant Syndrome (NMS), Tardive Dyskinesia, DRESS, and Stevens-Johnson syndrome. 8. Contraindications/Precautions Elderly: Avoid in dementia-related psychosis. Renal: Use IM formulations with caution due to the cyclodextrin excipient clearance. 9. Nursing Interventions Safety: Handle as a hazardous drug (Group 3). PO Admin: Administer whole; never crush or chew. IM Admin: Reconstitute ONLY with Sterile Water. Keep the patient recumbent for ≥30 mins post-injection to prevent severe hypotension. Monitor: Baseline/ongoing ECGs (QTc) and sodium levels (due to SIADH/hyponatremia risk). 10. Patient Education Take capsules whole, always with food, at roughly the same time daily. Immediately report palpitations, fainting, muscle stiffness, or rashes. 11. Black Box Warning/Antidote BBW: Increased mortality (typically heart failure or pneumonia) and increased stroke risk in elderly patients with dementia-related psychosis. 12. Nursing School Priority Summary Must Know: PO dosing strictly requires food for absorption; always monitor ECG for QT prolongation. Nice to Know: Ziprasidone is not removed by hemodialysis. Test Trap: Failing to keep IM patients flat for 30 minutes, risking orthostatic hypotension. Clinical Red Flag: Sudden fever, muscle rigidity (NMS), or arrhythmias. One-Sentence Memory Hook: "Ziprasidone zips the heart rhythm (QT risk) and needs a meal to zip through the gut."

MH PHARM | Perphenazine [Trilafon]

1. Medication Name/Class Trilafon (perphenazine). Class: First-Generation Antipsychotic (FGA); Phenothiazine Antiemetic. 2. Mechanism of Action Blocks postsynaptic dopamine D2 receptors in the mesolimbic system (reducing psychosis) and the chemoreceptor trigger zone (stopping emesis). It also causes alpha-1 adrenergic and moderate anticholinergic blockade. 3. Expected Action/Therapeutic Effect Decreased psychotic symptoms and resolution of severe nausea or vomiting. 4. Indications Common: Schizophrenia, severe nausea and vomiting. Off-Label: Severe behavioral or psychological symptoms of dementia (BPSD). 5. Pharmacokinetics Extensively metabolized in the liver (CYP2D6); contraindicated in significant hepatic impairment. It is highly protein-bound with a half-life of 9-12 hours. 6. Drug-Drug Interactions It acts as a relatively potent inhibitor of CYP2D6. Crucial administration rule: Do NOT mix oral concentrate with caffeine (coffee/cola), tannics (tea), or pectinates (apple juice). Dilute just prior to administration using only approved liquids like water, milk, or orange/tomato juice. 7. Side Effects vs Adverse Effects Common: Drowsiness, dry mouth, orthostatic hypotension, constipation, urinary retention. Adverse: Extrapyramidal symptoms (EPS - dystonia, pseudoparkinsonism, akathisia), tardive dyskinesia, QT prolongation. Life-Threatening: Neuroleptic Malignant Syndrome (NMS), agranulocytosis, seizures, stroke, cardiac arrest. 8. Contraindications/Precautions Avoid in geriatric patients with Parkinson's, delirium, dementia, or benign prostatic hyperplasia. Use cautiously in fall-risk patients due to CNS depression and hypotension. 9. Nursing Interventions Monitor sodium levels closely upon initiation/dose changes due to the risk of SIADH and hyponatremia. In long-term care, follow OBRA regulations requiring gradual dose reduction (GDR) attempts and documented medical necessity. Avoid spilling liquid on skin to prevent contact dermatitis. 10. Patient Education May take with food for stomach upset. Change positions slowly to avoid fainting. Immediately report muscle rigidity, high fever (NMS), abnormal involuntary movements (EPS), or signs of infection like a sore throat (agranulocytosis). 11. Black Box Warning BBW: Increased risk of death (typically heart failure or infection) and cerebrovascular events (stroke) in elderly patients treated for dementia-related psychosis. 12. Nursing School Priority Summary Must Know: Blocks dopamine, causing a high risk for EPS, tardive dyskinesia, and NMS. Nice to Know: Liquid concentrate has strict mixing rules; never mix with apple juice, coffee, or tea. Test Trap: Administering to a geriatric dementia patient without attempting non-pharmacologic interventions violates OBRA guidelines and triggers the Black Box Warning. Clinical Red Flag: Watch for sudden fever, sore throat (agranulocytosis), or muscle rigidity (NMS). One-Sentence Memory Hook: Perphenazine powerfully prevents psychosis and puking, but provokes parkinsonism and poses perils for the aging.

MH PHARM | Prolixin [Fluphenazine]

Medication Name/Class Generic/Brand: Fluphenazine / Prolixin Decanoate Class: First-Generation Antipsychotic (Phenothiazine) 2. Mechanism of Action Blocks postsynaptic D2 (dopamine) receptors in the mesolimbic system. Possesses weak anticholinergic and alpha1-adrenergic blocking effects. Strong D2 blockade reduces psychosis but directly causes extrapyramidal symptoms (EPS). 3. Expected Action/Therapeutic Effect Decreases dopamine neurotransmission to control psychotic symptoms. Provides antiemetic effects by blocking the chemoreceptor trigger zone. 4. Indications Priority Uses: Schizophrenia (maintenance and acute management). Acute agitation in psychotic disorders. Off-Label: Severe behavioral/psychological symptoms of dementia (strictly regulated by OBRA). 5. Pharmacokinetics Onset/Peak: Oral peaks in 2 hrs. Immediate IM peaks in 1.5-2 hrs. Depot IM/SubQ peaks in 8-10 hrs. Duration: Immediate IM lasts 6-8 hrs; Depot lasts 2-4 weeks. Metabolism: Liver; major CYP2D6 substrate and inhibitor. 6. Drug-Drug Interactions CNS depressants: Increase sedation and fall risk in the elderly. CYP2D6 substrates: Metabolism may be inhibited by fluphenazine. Food/Liquid Interaction: Oral concentrate MUST NOT be mixed with caffeine (coffee, cola), tannics (tea), or pectinates (apple juice). 7. Side Effects vs Adverse Effects Common: EPS (pseudoparkinsonism, akathisia, dystonia), sedation, anticholinergic effects (dry mouth), orthostatic hypotension. Severe/Life-Threatening: Neuroleptic Malignant Syndrome (NMS), Tardive Dyskinesia (TD), prolonged QT/Torsade de pointes, agranulocytosis, seizures. 8. Contraindications/Precautions Contraindicated: Hepatic impairment or liver damage. Precautions: Geriatric patients (Beers Criteria) due to high risk of falls, fractures, and anticholinergic effects. 9. Nursing Interventions Admin: Inject deeply into upper outer gluteal muscle; rotate sites. Do NOT dilute depot injections. Safety: Keep patient recumbent for 30 mins post-injection to minimize severe hypotension. Monitor: Sodium levels for SIADH risk. 10. Patient Education Take oral doses with food if GI upset occurs. Avoid spilling liquid preparations on skin/clothing. Rise slowly from sitting or lying down to manage orthostatic hypotension. 11. Black Box Warning/Antidote BBW: Increased mortality in elderly patients with dementia-related psychosis (deaths usually from heart failure, infections, or stroke). 12. Nursing School Priority Summary Must Know: Keep the patient flat for 30 minutes after injection to prevent severe hypotensive effects. Nice to Know: 10 mg of daily oral fluphenazine converts to ~12.5 mg of depot every 3 weeks. Test Trap: The oral concentrate has strict mixing rules—never mix with coffee, tea, or apple juice. Clinical Red Flag: Watch for potentially fatal NMS, TD, and blood dyscrasias.

MH PHARM | Chlorpromazine [Thorazine]

Chlorpromazine (Thorazine): Essential Clinical Profile 1. Mechanism of Action & Pharmacology Chlorpromazine is a first-generation phenothiazine antipsychotic and antiemetic. It blocks postsynaptic dopamine D2 receptors in the mesolimbic system, reducing psychosis but causing extrapyramidal symptoms (EPS). Dopamine blockade in the chemoreceptor trigger zone produces antiemetic effects. It exhibits strong anticholinergic and alpha-1-adrenergic receptor blocking properties, causing sedation and cardiovascular effects like profound hypotension. 2. Pharmacokinetics & Metabolism Oral bioavailability averages 32% due to extensive first-pass metabolism. It is 90% to 99% plasma protein-bound, and undergoes biphasic metabolism with a terminal half-life of 30 hours. Metabolism is primarily via CYP2D6, which chlorpromazine inhibits. Only 1% of the drug is excreted unchanged in urine, and it is not dialyzable. Peak antipsychotic effects may take 6 weeks to 6 months. 3. Core Indications & Dosing Parameters Approved for schizophrenia (adults start at 10-25 mg PO; up to 1000 mg/day max), severe pediatric behavioral problems (ADHD), intractable hiccups, tetanus adjunct, acute intermittent porphyria, and acute nausea/vomiting. Off-label uses include acute migraines, neonatal abstinence syndrome, and ICU agitation. It is a last-line option for pregnancy-induced nausea. 4. High-Risk Administration Protocols Intravenous (IV) administration is restricted to surgical nausea, severe hiccups, or tetanus. It must NEVER be injected undiluted. Dilute with 0.9% NaCl to 1 mg/mL; maximum infusion rate is 1 mg/min for adults (0.5 mg/min for children). IM injections must be given slowly and deeply into the upper outer buttock. Blood pressure monitoring is mandatory; patients must remain completely recumbent for at least 30 minutes following IM/IV doses to prevent severe orthostatic hypotension. 5. Boxed Warning & Geriatric Precautions A strict Boxed Warning notes it is not approved for dementia-related psychosis in the elderly due to significantly increased mortality risks (heart failure, sudden death, infections) and stroke. The Beers Criteria classifies it as a potentially inappropriate medication (PIM) due to risks of tardive dyskinesia, falls, and anticholinergic toxicity. Long-term care use is regulated by OBRA guidelines, requiring gradual dose reduction attempts in two separate quarters in the first year. 6. Major Adverse Reactions Life-threatening reactions require immediate intervention: neuroleptic malignant syndrome (NMS), tardive dyskinesia, QT prolongation, seizures, and agranulocytosis. Common effects include drowsiness, xerostomia, photosensitivity, and severe hypotension. Discontinue therapy immediately if jaundice develops. Monitor sodium closely due to SIADH risk.

MH PHARM | Haldol

1. Medication Name and Class Haloperidol (Haldol) is a high-potency first-generation (conventional) antipsychotic structurally related to droperidol. 2. Mechanism of Action Haloperidol blocks central postsynaptic dopamine (D-2) receptors in the mesolimbic pathway, which treats positive symptoms of schizophrenia like hallucinations and delusions. However, dopamine blockade in the nigrostriatal pathway causes extrapyramidal symptoms (EPS), while blockade in the tuberoinfundibular tract causes hyperprolactinemia. It has weak affinity for muscarinic, alpha-1, and H-1 receptors, meaning it causes less sedation, reflex tachycardia, and orthostatic hypotension compared to other antipsychotics. 3. Indications FDA-approved uses include schizophrenia, Tourette's disorder, severe behavioral disorders in children, and acute agitation. Off-label uses include ICU delirium, persistent hiccups, chemotherapy-induced nausea, and severe behavioral symptoms of dementia. 4. Boxed Warning and Geriatric Precautions Haloperidol carries a Boxed Warning regarding its use in geriatric patients with dementia-related psychosis. It is not FDA-approved for this population due to an increased risk of mortality, primarily from heart failure, sudden death, and infections like pneumonia. Additionally, there is an increased risk of cerebrovascular adverse events, including fatal strokes and transient ischemic attacks. The Beers Criteria considers it potentially inappropriate for elderly patients except in specific cases like schizophrenia or chemotherapy-induced nausea. Use for dementia behavioral symptoms must meet strict federal OBRA guidelines, primarily when the patient is a substantial threat to self or others. Due to the risk of hyponatremia and SIADH, sodium levels should be monitored closely. 5. Pharmacokinetics and Administration Oral formulations should be taken with food to minimize GI irritation. Oral concentrates can be mixed with food or beverages, but not coffee or tea, which cause precipitation. Nurses should avoid skin contact with the concentrate to prevent contact dermatitis. Intramuscular (IM) lactate is an immediate-release injection that peaks in 20 to 40 minutes. Max adult dose is 20 mg/day. Intramuscular (IM) decanoate is a depot injection in sesame oil used for prolonged therapy. It must be administered deep IM, never IV, with a maximum of 3 mL per site using a 21-gauge needle. Peak concentrations occur after about 6 days, and the half-life is roughly 3 weeks. Patients must be stabilized on oral haloperidol before converting to the depot formulation. Intravenous (IV) administration of haloperidol is not FDA-approved in any population. If used off-label (e.g., for ICU delirium), it carries a high risk of QT prolongation, Torsade de Pointes (TdP), and arrhythmias, requiring strict ECG monitoring. 6. Major Adverse Effects Severe, life-threatening adverse effects include neuroleptic malignant syndrome (NMS), tardive dyskinesia, QT prolongation, Torsade de Pointes, cardiac arrest, seizures, and agranulocytosis. Moderate effects include severe EPS (pseudoparkinsonism, akathisia, dystonic reactions) and hyperprolactinemia (galactorrhea, amenorrhea, impotence). Mild effects include drowsiness, dry mouth, and tremors. 7. Drug Interactions and Metabolism Haloperidol is extensively metabolized in the liver by CYP2D6 and CYP3A4. Slow metabolizers of CYP2D6 are at increased risk for EPS due to delayed drug clearance. Co-administration with CYP3A4 or CYP2D6 inhibitors can increase haloperidol concentrations and the risk of QT prolongation. Avoid or reduce dosage in patients with severe hepatic impairment. No dosage adjustments are needed for renal impairment.

MH | Foundations of Mental Health

Mental Health and Illness Mental health is a positive state of complete physical, mental, and social well-being, characterized by effective coping and satisfying relationships. Mental illness involves disorders affecting mood, behavior, and thinking that cause significant distress or impaired functioning. Both are dynamic states influenced by individual (biologic makeup), interpersonal (communication), and social determinants (resources, discrimination). Diagnostic Framework (DSM-5-TR) The DSM-5-TR is the standard taxonomy used by clinicians to diagnose psychiatric illnesses. It provides a standardized nomenclature, presents defining symptoms to differentiate diagnoses, and identifies underlying causes, including psychosocial and environmental problems that affect treatment. Deinstitutionalization & The "Revolving Door" The 1950s development of psychopharmacology dramatically reduced psychotic thinking, paving the way for shorter hospital stays. In 1963, the U.S. enacted the Community Mental Health Centers Construction Act, initiating deinstitutionalization—shifting care from long-term state institutions to community-based facilities. However, community resources remained inadequately funded, leading to the "revolving door effect". This phenomenon is characterized by short, unplanned hospital stays where patients show brief improvement but are discharged before stabilization, resulting in rapid decompensation, severe emergency department boarding, and frequent readmissions. This systemic failure heavily contributes to high rates of homelessness among the mentally ill. Psychiatric Nursing Practice Modern psychiatric nursing is rooted in the theories of Hildegard Peplau (therapeutic nurse-client relationship) and June Mellow (meeting immediate psychosocial needs). The American Psychiatric Nurses Association (APNA) outlines standards of practice covering basic functions (counseling, milieu therapy, administering medications) and advanced functions (psychotherapy, prescriptive authority). Therapeutic Boundaries and Self-Awareness For students, fears regarding safety are common, but psychiatric clients are significantly more likely to harm themselves than others. Effective practice requires establishing strong professional boundaries and utilizing therapeutic communication, where genuine listening is far more important than worrying about "saying the right thing". Central to psychiatric nursing is self-awareness: the active process of recognizing one's own feelings, beliefs, and attitudes. Because a nurse's values will inevitably conflict with a client's lifestyle, the nurse must use reflection, journaling, or clinical supervision to separate personal beliefs from professional care. This ensures biases do not hinder the delivery of safe, nonjudgmental treatment.

MH | Treatment Settings and Therapeutic Programs

Evolution of Mental Health Settings Mental health care has shifted from long-term institutionalization to short-stay hospitalizations focused on rapid assessment, symptom stabilization, and discharge planning. Due to managed care constraints, inpatient stays are shorter and reserved for higher acuity clients. Alternatives like crisis resolution teams (CRTs), respite care, and partial hospitalization programs (PHPs) are cost-effective methods to prevent hospital readmission and support community living. Telepsychiatry also expands access, especially in rural and isolated areas. Discharge Planning & Community Integration The adequacy of a discharge plan is the strongest predictor of how long a client remains in the community. Optimal discharge planning is frequently impeded by poverty, substance use, criminal behavior, medication nonadherence, and suicidal ideation. When these barriers force clients into marginal discharge plans, rapid rehospitalization is highly likely. The client’s living environment—whether a halfway house, group home, or independent living—is often more predictive of their success than their specific psychiatric illness. Psychiatric Rehabilitation & Recovery Modern care uses a recovery model extending beyond symptom control to focus on empowerment, community reintegration, and personal growth. Two high-yield community frameworks include: Assertive Community Treatment (ACT): A highly effective, multidisciplinary approach that provides intensive, 24/7, direct services in the client's own home or community. It focuses on real-life skills, medication management, and problem-solving without time constraints. Clubhouse Model: An intentional community guaranteeing members a place to go, meaningful work, and lifetime relationships. It focuses on health rather than illness, and medication adherence is not a requirement for participation. Vulnerable Populations with Complex Needs Homelessness: Providing housing alone is insufficient; clients also require psychosocial rehabilitation, peer support, and vocational training to improve overall outcomes. Incarceration: The "criminalization of mental illness" has resulted in jails becoming makeshift asylums due to deinstitutionalization, rigid civil commitment criteria, and inadequate community support. Veterans: Military veterans exhibit significantly higher rates of PTSD, major depression, substance use, and suicide compared to civilians. The Psychiatric Nurse's Role The interdisciplinary team relies heavily on the psychiatric nurse, who is ideally suited for case management. Unlike other disciplines, registered nurses possess a holistic foundation allowing them to manage complex psychopharmacology, assess physiological comorbidities, monitor side effects, and provide vital patient education. Furthermore, the nurse must expand their skills to support autonomous, client-centered decisions, even when those choices diverge from traditional expectations, to embrace true recovery.

MH | Patient Response to Illness

Patient responses to mental illness and treatment are never uniform; they are distinctly shaped by an overlapping mosaic of individual, interpersonal, and cultural factors. Mastering this breakdown of influences is essential for safe, holistic psychiatric nursing care. 1. Individual Factors: Biology, Development, and Coping Age at onset strongly predicts a disease's prognosis. For example, younger onset of schizophrenia yields poorer outcomes because the patient has less developed coping skills and personal identity. Developmentally, patients must successfully navigate Erikson’s psychosocial stages (such as trust versus mistrust); getting "stuck" at any stage severely limits their ability to manage future stress and illness. Genetics and physical health play an unchangeable yet profound role. Pharmacogenetics dictate how differently patients metabolize psychotropic medications, which directly determines drug efficacy and the severity of side effects. Poor metabolizers face higher toxicity risks, demanding vigilant nursing observation. Internally, a patient's response to stress is buffered by psychological traits: self-efficacy (the empowering belief that personal efforts affect life events), hardiness (viewing stress as a challenge rather than a threat), and resilience (the ability to adapt to adversity and minimize PTSD). Furthermore, spirituality and hope act as major coping devices, directly decreasing psychiatric symptoms. 2. Interpersonal Factors: Belonging and Support Systems A sense of belonging is a basic human need that decreases anxiety and limits isolation. Social support networks provide emotional and functional sustenance, but there is a catch: support is only effective if the patient perceives it as genuinely helpful and responsive to their specific needs. Family members remain a vital resource for psychiatric recovery. 3. Cultural Factors: Humility over Assumptions The highest-yield concept in transcultural nursing is cultural humility—a lifelong process of remaining inquisitive, open, and avoiding stereotypes. Because individual variation within cultural groups is vast, nurses must never make assumptions; you must directly ask the patient about their beliefs and preferences. Mental illness and suicide often carry severe cultural stigma, causing patients to view their symptoms as a failure, which delays treatment. Using the Giger assessment model, nurses must evaluate: Communication & Space: differing norms around eye contact, physical distance, and supportive touch. Social Organization: determining if health care decisions are made individually or collectively by the family. Time Orientation: assessing if a patient views time precisely or approximately, which affects perceived medication noncompliance. Beliefs: whether the patient views illness causes as natural, unnatural/supernatural, or biomedical. 4. Social Determinants of Health (SDOH) Environmental conditions radically affect mental health risks. Poverty, discrimination, poor housing, and low health literacy frequently derail treatment plans. Nurses must assess these barriers; prescribing medication is useless if the patient cannot afford it or lacks the literacy to follow instructions.

MH | Legal and Ethical Issues

1. Client Rights & Admission Types Psychiatric clients retain all civil rights (e.g., refusing treatment, receiving sealed mail, having visitors) unless restricted for verifiable, documented safety reasons. Voluntary Admission: Clients agree to treatment and can request discharge. If they pose a danger, the psychiatrist can file for involuntary commitment. Involuntary Commitment: Permitted only when a client is a danger to themselves or others. Emergency detention lasts 48 to 72 hours until a hearing. Patients lose the right to leave but retain all other civil rights. Mandatory Outpatient Treatment: Court-ordered care to prevent relapse for severe mental illness. Guardianship: For legally incompetent clients, a court-appointed guardian provides informed consent; the client loses the right to sign contracts. 2. Restraints, Seclusion & Least Restrictive Environment Clients have a right to treatment in the least restrictive setting. Restraints (human, mechanical, chemical) and seclusion are absolute last resorts. Criteria: Permitted only when the client is imminently dangerous and all other de-escalation methods have failed. Strict Protocols: Requires a face-to-face evaluation by a licensed practitioner within 1 hour. Adults need a provider's order every 4 hours and nursing assessments every 1 to 2 hours. Monitoring: Restrained clients require continuous one-to-one monitoring. Secluded clients require one-to-one monitoring for the first hour, followed by audio and video monitoring. Debriefing is required within 24 hours. 3. Confidentiality & Legal Exceptions HIPAA: Strictly protects health information, which can sometimes limit family collaboration in a crisis. Duty to Warn: Based on the Tarasoff decision, confidentiality must be breached if a client poses a serious, foreseeable threat to an identifiable, accessible third party. Clinicians must warn the targeted person. Insanity Defense: Rarely used and rarely successful. Evaluated using rules like M’Naghten (inability to know right from wrong). 4. Nursing Liability & Torts Nurses must meet standards of care to avoid torts. Unintentional Torts: Include negligence and malpractice. Malpractice requires proving four elements: duty, breach, injury, and causation. Mental health lawsuits often stem from patient suicides. Intentional Torts: Include assault (causing fear of offensive touching), battery (unwarranted or harmful physical contact), and false imprisonment (unjustifiable detention, like inappropriate restraint use). 5. Core Ethical Principles Ethical dilemmas frequently pit patient autonomy against the public good, also known as utilitarianism. Autonomy: The right to self-determination. Beneficence: The duty to promote good. Nonmaleficence: The duty to do no harm. Justice: Treating all people fairly. Veracity: The duty to be honest. Fidelity: Honoring commitments.

19 de 34